A major computer manufacturer engaged CRA to investigate the royalty payments of several licensees in Europe and Asia of a patent for an important computer component. CRA conducted extensive pre-site analyses in preparation for on-site visits to each licensee, and identified several million dollars in underpaid royalties.
Biosimilars: Economic Issues for IP Litigation
In July 2021, the U.S. Food and Drug Administration granted a determination of interchangeability to a biosimilar drug for the first time. This approval has...